Fox Run Management L.L.C. Takes $270,000 Position in 10x Genomics $TXG

Key Points

• Fox Run Management L.L.C. has acquired 30,978 shares of 10x Genomics ($TXG), valued at approximately $270,000, as part of its new position established in the first quarter.
• A significant number of hedge funds have also increased their stakes in 10x Genomics, with 84.68% of the stock currently held by institutional investors.
• 10x Genomics has recently reported a quarterly EPS of $0.28, surpassing consensus estimates by a significant margin, with revenues of $172.91 million compared to expectations of $139.36 million.

Fox Run Management L.L.C. acquired a new stake in 10x Genomics (NASDAQ:TXG - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 30,978 shares of the company's stock, valued at approximately $270,000.

Other institutional investors have also modified their holdings of the company. GAMMA Investing LLC raised its position in 10x Genomics by 81.8% during the first quarter. GAMMA Investing LLC now owns 3,586 shares of the company's stock worth $31,000 after acquiring an additional 1,614 shares during the last quarter. Xponance Inc. grew its position in shares of 10x Genomics by 17.4% in the first quarter. Xponance Inc. now owns 12,010 shares of the company's stock valued at $105,000 after purchasing an additional 1,778 shares during the period. GF Fund Management CO. LTD. purchased a new position in 10x Genomics during the fourth quarter worth about $32,000. Signaturefd LLC increased its stake in shares of 10x Genomics by 134.3% during the 1st quarter. Signaturefd LLC now owns 4,203 shares of the company's stock valued at $37,000 after acquiring an additional 2,409 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC lifted its holdings in shares of 10x Genomics by 9.0% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 31,061 shares of the company's stock worth $271,000 after acquiring an additional 2,564 shares during the period. 84.68% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms have recently issued reports on TXG. UBS Group increased their price objective on shares of 10x Genomics from $12.00 to $13.00 and gave the stock a "neutral" rating in a research report on Friday, August 8th. JPMorgan Chase & Co. decreased their target price on shares of 10x Genomics from $12.00 to $9.00 and set a "neutral" rating for the company in a research note on Friday, May 9th. Canaccord Genuity Group set a $16.00 price target on 10x Genomics in a research note on Monday, August 11th. Morgan Stanley dropped their price objective on shares of 10x Genomics from $18.00 to $17.00 and set an "overweight" rating on the stock in a research note on Tuesday, August 12th. Finally, Wall Street Zen raised 10x Genomics from a "hold" rating to a "buy" rating in a research report on Saturday, August 9th. Six research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $13.54.

10x Genomics Stock Up 9.2%

Shares of TXG stock traded up $1.20 during trading hours on Friday, reaching $14.30. The company's stock had a trading volume of 3,446,087 shares, compared to its average volume of 3,399,679. The company has a market capitalization of $1.78 billion, a price-to-earnings ratio of -20.43 and a beta of 2.03. 10x Genomics has a fifty-two week low of $6.78 and a fifty-two week high of $24.76. The firm's 50 day simple moving average is $12.59 and its 200-day simple moving average is $10.68.

10x Genomics (NASDAQ:TXG - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported $0.28 earnings per share for the quarter, beating analysts' consensus estimates of ($0.35) by $0.63. The firm had revenue of $172.91 million for the quarter, compared to analyst estimates of $139.36 million. 10x Genomics had a negative net margin of 13.13% and a negative return on equity of 12.88%. The company's quarterly revenue was up 12.9% on a year-over-year basis. During the same quarter last year, the business posted ($0.32) earnings per share. 10x Genomics has set its Q3 2025 guidance at EPS. Sell-side analysts predict that 10x Genomics will post -1.43 earnings per share for the current year.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.